Atosiban Improves Implantation and Pregnancy Rates in Patients With Repeated Implantation Failure

An Sinh Hospital

Status: Completed

Conditions: Repeated Implantation Failure

Treatments: Drug: atosiban

Study type: Interventional

Funder types: Other

Identifiers

NCT01493440

IVFAS1103

Details and patient eligibility

About

Atosiban, administered at embryo transfer, can improve the implantation rate and the clinical pregnancy rate in patients with repeated implantation failure undergoing IVF-ET (in-vitro fertilization and embryo transfer).

Full description

Atosiban is a mixed oxytocin and vasopressin V1A receptor antagonist.Combined antagonism at oxytocin and vasopressin V1A receptors reduces uterine contractions with a corresponding decrease in intrauterine production of prostaglandin F2alpha and improved uterine blood supply. These effects are of potential benefit for implantation support during IVF-ET cycles.

Enrollment: 71 patients

Sex: Female

Volunteers: No Healthy Volunteers

Inclusion criteria

• had repeated implantation failure
• have at least 1 good quality embryo for transfer

Exclusion criteria

• uterine abnormalities that could compromise the implantation process (e.g. fibroids, endometrial polyp, bicornuate uterus, adhesion of uterine cavity)

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

71 participants in 1 patient group

Atosiban

Other group

Treatment:

Drug: atosiban